Paignton

Researchers are evaluating the safety, antiviral biomarker responses, and effectiveness of inhaled SNG001 in patients who require invasive mechanical ventilation due to respiratory virus infections such as influenza A or B, RSV, rhinovirus, adenovirus, parainfluenza, human metapneumovirus, and coronaviruses including SARS-CoV-2. This Phase 2 study aims to see if SNG001 can help clear the virus faster and reduce death rates compared to standard care. The study is divided into two parts focusing on different age groups and immunocompromising conditions. Participants will receive either SNG001 or a placebo nebuliser solution once daily for up to 14 days while hospitalized, in addition to standard care. In Part 1, patients aged 50 years or older will be treated to assess safety. In Part 2, patients aged 18 to under 50 with immunocompromising conditions, as well as those 50 years or older with or without such conditions, will be treated to evaluate efficacy. Treatment begins within 48 hours of intubation. Throughout the study, safety will be monitored by tracking adverse events and serious adverse events up to 28 days after randomization, along with all-cause mortality within the same period. Participants will undergo virus testing and clinical assessments, and women of childbearing potential must have a negative pregnancy test. The total participation duration includes hospitalization during treatment and follow-up for safety and outcome measures.